Abstract 397P
Background
Dexamethasone is the standard premedication for preventing nausea, vomiting and hypersensitivity reactions but the incidence of oxaliplatin hypersensitivity is varied. This study aimed to compare the incidence of any grade of oxaliplatin hypersensitivity between using the Y-site co-infusion of oxaliplatin and dexamethasone or standard premedication with intravenous dexamethasone to prevent hypersensitivity reactions (HSRs) and also to compare the degree of venous pain, objective response rate (ORR), progression free survival (PFS) and common adverse events.
Methods
Patients with stage III and IV of colorectal cancer who received capecitabine and oxaliplatin (CAPEOX) regimen at least 3 cycles from March 2022 to March 2023 were enrolled. At the 4th cycle, all enrolled patients were randomly assigned to receive either Y-site co-infusion of oxaliplatin and dexamethasone (arm A) or standard premedication with intravenous dexamethasone followed by Y-site co-infusion of oxaliplatin and placebo (arm B). The incidence of HSRs and the degree of venous pain between arm A and arm B were analyzed by using Chi-square and log-rank test was used for evaluate PFS.
Results
Nineteen of 37 patients were enrolled to arm A, and 18 of 37 patients were enrolled to arm B. There was no incidence of any grade of HSRs in both groups. The incidence of severe venous pain (grade 3) based on WHO classification between arm A and arm B were 16% and 39%, respectively (relative risk 0.41, 95% CI 0.12-1.33, P-value=0.114). The mean change of venous pain score between arm A and arm B based on numerical rating scale (NRS) were 5.01 and 5.64, respectively (P-value=0.402). There were no differences in ORR, PFS and common adverse events between two groups.
Conclusions
There was no incidence of any grade of HSRs between groups, so we could not conclude that using the Y-site co-infusion of oxaliplatin and dexamethasone was effective than standard premedication with intravenous dexamethasone for preventing HSRs from oxaliplatin administration. However, an incidence of severe venous pain may be reduced via through Y-site co-infusion of oxaliplatin and dexamethasone.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Institutional Review Board of Royal Thai Army Medical Department (IRBRTA R194h/64).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract